BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 23012669)

  • 1. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
    Valle JW; Furuse J; Jitlal M; Beare S; Mizuno N; Wasan H; Bridgewater J; Okusaka T
    Ann Oncol; 2014 Feb; 25(2):391-8. PubMed ID: 24351397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
    Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
    [No Abstract]   [Full Text] [Related]  

  • 7. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
    Lee JK; Capanu M; O'Reilly EM; Ma J; Chou JF; Shia J; Katz SS; Gansukh B; Reidy-Lagunes D; Segal NH; Yu KH; Chung KY; Saltz LB; Abou-Alfa GK
    Br J Cancer; 2013 Aug; 109(4):915-9. PubMed ID: 23900219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
    Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
    Iqbal S; Rankin C; Lenz HJ; Gold PJ; Ahmad SA; El-Khoueiry AB; Messino MJ; Holcombe RF; Blanke CD
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1595-602. PubMed ID: 21556747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
    Iyer RV; Gibbs J; Kuvshinoff B; Fakih M; Kepner J; Soehnlein N; Lawrence D; Javle MM
    Ann Surg Oncol; 2007 Nov; 14(11):3202-9. PubMed ID: 17705089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Knox JJ; Hedley D; Oza A; Siu LL; Pond GR; Moore MJ
    Ann Oncol; 2004 May; 15(5):770-4. PubMed ID: 15111345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
    Meyerhardt JA; Zhu AX; Stuart K; Ryan DP; Blaszkowsky L; Lehman N; Earle CC; Kulke MH; Bhargava P; Fuchs CS
    Dig Dis Sci; 2008 Feb; 53(2):564-70. PubMed ID: 17597402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
    Guion-Dusserre JF; Lorgis V; Vincent J; Bengrine L; Ghiringhelli F
    World J Gastroenterol; 2015 Feb; 21(7):2096-101. PubMed ID: 25717243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.
    Kato A; Shimizu H; Ohtsuka M; Yoshidome H; Yoshitomi H; Furukawa K; Takeuchi D; Takayashiki T; Kimura F; Miyazaki M
    Ann Surg Oncol; 2013 Jan; 20(1):318-24. PubMed ID: 23149849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.